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Abstract
Background: African trypanosomes are capable of both pyrimidine biosynthesis and salvage of preformed pyrimidines from
the host, but it is unknown whether either process is essential to the parasite.
Methodology/Principal Findings: Pyrimidine requirements for growth were investigated using strictly pyrimidine-free
media, with or without single added pyrimidine sources. Growth rates of wild-type bloodstream form Trypanosoma brucei
brucei were unchanged in pyrimidine-free medium. The essentiality of the de novo pyrimidine biosynthesis pathway was
studied by knocking out the PYR6-5 locus that produces a fusion product of orotate phosphoribosyltransferase (OPRT) and
Orotidine Monophosphate Decarboxylase (OMPDCase). The pyrimidine auxotroph was dependent on a suitable
extracellular pyrimidine source. Pyrimidine starvation was rapidly lethal and non-reversible, causing incomplete DNA
content in new cells. The phenotype could be rescued by addition of uracil; supplementation with uridine, 29deoxyuridine,
and cytidine allowed a diminished growth rate and density. PYR6-52/2 trypanosomes were more sensitive to pyrimidine
antimetabolites and displayed increased uracil transport rates and uridine phosphorylase activity. Pyrimidine auxotrophs
were able to infect mice although the infection developed much more slowly than infection with the parental, prototrophic
trypanosome line.
Conclusions/Significance: Pyrimidine salvage was not an essential function for bloodstream T. b. brucei. However,
trypanosomes lacking de novo pyrimidine biosynthesis are completely dependent on an extracellular pyrimidine source,
strongly preferring uracil, and display reduced infectivity. As T. brucei are able to salvage sufficient pyrimidines from the host
environment, the pyrimidine biosynthesis pathway is not a viable drug target, although any interruption of pyrimidine
supply was lethal.
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Introduction
Human African Trypanosomiasis (HAT, or sleeping sickness) is
caused by infection with the protozoan parasites Trypanosoma brucei
gambiense and T. b. rhodesiense in West Africa and in East and
Southern Africa, respectively. In addition the subspecies T. b. brucei
and the other non-human infective species T. vivax and T. congolense
cause the veterinary condition African Animal Trypanosomiasis
(AAT, or nagana) in livestock in much of sub-Saharan Africa. Both
diseases continue to have profound health and economic
implications in poor and isolated populations of the region. This
problem is exacerbated by the inadequacies of the existing drugs,
especially their toxicity, and a parenteral route of administration
[1], and by high levels of treatment failure that reach about 30%
in some areas [2]. The drug of choice for late stage HAT,
eflornithine, is currently administered in the form of nifurtimox
and eflornithine combination therapy (NECT) and is not suitable
for T. b. rhodesiense infection, which still has to be treated by
suramin or melarsoprol, for Stage I (periphery) or Stage II (central
nervous system) disease, respectively; both have severe adverse
effects on patients [1,2]. The use of NECT lowers cost and toxicity
but may not halt the spread of eflornithine resistance indefinitely
[3,4]. The quest for new drugs led to the study of nucleotide
salvage and biosynthesis in protozoa, and initially focused on
inhibitors of purine metabolism, as pathogenic protozoan parasites
(but not free-living protists) have lost the de novo purine biosynthesis
pathways [5,6]. However, in many protozoa, including kineto-
plastid parasites, redundancy of purine transporters [7,8,9] and
interconversion pathways [10,11,12] makes therapy based on
purine metabolism inhibitors extremely difficult to achieve.
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In contrast, most parasitic protozoa are fully capable of
synthesizing the pyrimidine ring de novo [10] and yet are also
capable of salvaging pyrimidine nucleosides and/or nucleobases
[13,14,15,16]. Exceptions are Plasmodium spp, which are incapable
of pyrimidine salvage [17], and the amitochondriate protozoa
Trichomonas vaginalis, Tritrichomonas foetus and Giardia spp, which lack
the de novo biosynthesis pathway [18,19]. While possession of both
the biosynthesis and salvage routes would appear to make
pyrimidine metabolism an unattractive drug target, it has not
been established whether either pyrimidine biosynthesis or salvage
is essential in African trypanosomes. Moreover, the salvage and
biosynthesis pathways actually share most of the pyrimidine
metabolizing enzymes, many of which have now been shown to be
essential because (in contrast to purine metabolism) there is little or
no redundancy in the pathways. For example, dihydrofolate
reductase - thymidylate synthase (DHFR-TS) is essential in
trypanosomes and its knockout can only be rescued by high levels
of thymidine [20], and CTP synthetase is essential as T. b. brucei
are unable to incorporate extracellular cytosine or cytidine in their
nucleic acids [21]. Furthermore, T. b. brucei deoxyuridine 59-
triphosphate nucleotidohydrolase (dUTPase) was recently shown
to be essential [22] and it is clear that several other enzymes of the
same pathways may equally be good drug targets.
However, it is as yet unclear whether either the uptake of
extracellular pyrimidines or the de novo biosynthesis of the first
pyrimidine nucleotide, UMP, is essential in kinetoplastid parasites.
We have previously shown that in procyclic T. b. brucei pyrimidines
are mainly taken up through the TbU1 uracil transporter [23,16]
and recently completed a study of pyrimidine transport activities in
bloodstream form T. b. brucei showing the presence of only one
high affinity uracil transporter, TbU3, and almost no uptake of
other pyrimidines at physiological levels [24]. A previous study, by
Arakaki et al [25] showed that RNAi disruption of one of the
biosynthesis enzymes, dihydroorotate dehydrogenase, led to
impaired growth which could be compensated for by pyrimidine
uptake. The rescue by extracellular uracil, however, was not
observed in the presence of the TbU3 inhibitor 5-fluorouracil [25].
In the present study we simulated complete inhibition of
pyrimidine salvage by in vitro growth in pyrimidine-free medium
and inhibition of de novo biosynthesis through the construction of a
genetic deletion mutant lacking the final step of the pyrimidine
biosynthesis pathway, which in trypanosomes is a fusion of the two
enzymes Orotidine Monophosphate Decarboxylase (PYR6,
OMPDCase) and orotate phosphoribosyltransferase (PYR5,
OPRT) [26,27]. The PYR6-52/2 trypanosomes were character-
ized in vitro and in vivo. While they were completely non-viable in
the absence of pyrimidines in vitro, they were able to grow on low
levels of pyrimidines, similar as reported for Leishmania donovani
promastigotes [28]. The activity of the TbU3 transporter, and
expression of Uridine Phosphorylase were both significantly
increased when PYR6-52/2 trypanosomes were shifted to pyrim-
idine-free conditions. However, the observation that these
parasites were able to establish an infection in mice showed that
pyrimidine biosynthesis is not essential in vivo, with pyrimidine
salvage from the blood sufficient for T. brucei viability and growth.
Materials and Methods
Ethics statement
The maintenance and care of experimental animals complied
with the appropriate legislation; the UK Animals (Scientific
Procedures) Act, 1986, and with the national and University of
Glasgow maintenance and care guidelines. All procedures were
carried out by trained, registered and licensed animal workers.
Care of animals was done by professional staff in the designated
University of Glasgow facility under supervision of qualified
Veterinarians. Mice infected with trypanosomes were humanely
euthanized before becoming seriously ill from the infection.
Approval for these experiments was explicitly granted by the
UK Home Office, project licence PPL 60/5760 and personal
licence PIL60/2328.
Culture of trypanosomes
Bloodstream forms of T. b. brucei strain 427 were routinely
cultured in HMI-9 medium [29] obtained from Invitrogen,
supplemented with 10% Heat Inactivated Fetal Bovine Serum
Gold (FBS; PAA Laboratories) in culture flasks, at 37uC, in a 5%
CO2 atmosphere. Where indicated, trypanosomes were grown in a
pyrimidine-free medium that was identical to the standard HMI-
9/FBS, except that it did not contain thymidine (or any other
pyrimidines) and that the serum was first thoroughly dialysed (12–
14 kDa cut-off) against phosphate-buffered saline pH 7.4); this
medium is referred to as HMI-9-tmd whereas the standard medium
is simply referred to as HMI-9. The dialysis details and the exact
composition of the HMI-9 and HMI-9-tmd media are given in the
Supplementary materials.
Transport of [3H]-uracil and [3H]-uridine
Transport assays were performed exactly as described [30,31].
Briefly, trypanosomes were washed into the appropriate assay
buffer (AB; 33 mM HEPES, 98 mM NaCl, 4.6 mM KCl,
0.55 mM CaCl2, 0.07 mM MgSO4, 5.8 mM NaH2PO4,
0.3 mM MgCl2, 23 mM NaHCO3, 14 mM glucose, pH 7.3) to
a final concentration of 108 cells ml21. 100 ml cell suspension was
incubated with either [5,6-3H]-uracil (Perkin Elmer, 40.3 Ci/
mmol) or [5,6-3H]-uridine (American Radiolabeled Chemicals
Inc, 30 Ci/mmol) at concentrations indicated in the results
section, in the presence or absence of unlabeled substrate or other
competitive inhibitors. The incubation was stopped after a
predetermined interval using 1 ml of an ice-cold 1-mM solution
of unlabeled substrate (uracil or uridine) and immediate centrifu-
gation through oil (13,0006g) for 1 min. The resulting cell pellet
was transferred to a scintillation tube and radioactivity was
determined by liquid scintillation counting. The results were
plotted to appropriate equations for linear or non-linear regression
using the Prism 5 software package (GraphPad) after correction for
non-specific association of radiolabel with the pellet, as described
[30].
Generation of auxotrophic T. brucei bloodstream forms
The plasmid pLHTL-PYR6-5 [27] was generously donated by
Professor George Cross of Rockefeller University, New York, NY.
This construct contains a hygromycin resistance cassette (hygro-
mycin B phosphotransferase) and a negative selection marker,
Herpes simplex Thymidine Kinase (HSVTK) open reading frame
between loxP domains [32] and is targeted to the PYR6-5 locus by
flanking sequences of 496 bp immediately downstream of the
target locus and of 365 bp commencing 134 bp upstream of the
ORF.
Bloodstream forms of T. brucei s427 were cultivated to a density
of ,1–26107 cells ml21 and washed into Human T-Cell Solution
for transfection with the LHTL-PYR6-5 cassette (liberated by
digestion with PvuII) using an Amaxa Nucleofactor electroporator
exactly as described [27], creating a PYR6-5+/2 strain. Transfor-
mants were grown and cloned out in standard HMI-9 containing
hygromycin (2 mg ml21) and loss of the second PYR6-5 allele was
induced by exposure of the clonal lines to 100 mM 5-fluoroorotic
acid (5FOA; Sigma), resulting in a PYR6-52/2 strain, exactly as
Pyrimidine Auxotrophy in Trypanosoma brucei
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described [27], which was cloned by limiting dilution. PYR6-5
single and double knockout clones were confirmed by PCR. DNA
was extracted from WT s427, and from the single and double
PYR6-5 knockout strains using a DNeasy Blood and Tissue Kit
(Qiagen). Primers were designed to amplify an 870 bp part of the
PYR6-5 gene. PCR was performed on 200 ng of the isolated DNA
using forward (59 GTTCTCGAGTGCAAGCGGAT) and reverse
(59CACAATGCGGTCAAACTGCA) primers annealing at 56uC
and extension at 72uC for 60 s. A Southern blot was also
performed to confirm knockouts, using restricted digest of 10 mg
DNA and blotting performed as described [33], using DNA probes
specific for the PYR6-5 and hygromycin B phosphotransferase
genes. The PYR6-5 probe was generated using the primers and
conditions given above for the PCR confirmation, whilst the
hygromycin probe was generated by a PCR using forward
(59ATGAAAAAGCCTGAACTCAC) and reverse (59ACTC-
TATTCCTTTGCCCTCG) primers annealing at 55uC and
extension at 72uC for 60 s.
Growth analysis
Growth of WT and PYR6-52/2 strains was assessed in standard
HMI-9 and in HMI-9-tmd supplemented with specific pyrimidines
as indicated in the text. Cells were seeded at 16105 cells ml21 and
for this purpose grown in 12-well plates, with each condition set up
in 2 wells; incubation was at 37uC and 5% CO2. Cells were
counted every 12 or 24 h. The experiment was performed
independently on three separate occasions.
Alamar blue drug sensitivity assays
Sensitivities of PYR6-52/2 and s427-WT cells to 5-fluorouracil,
5-fluoroorotic acid, 5-fluorouridine, 5-fluoro-29deoxyuridine and
5-fluoro-29deoxycytidine (all Sigma) were determined using the
Alamar Blue assay exactly as described by [34,35], using a
FLUOstar Optima (BMG Labtech, Durham, NC); lexc was
544 nm and lem was 620 nm. Seeding density was 10
5 per well
(final volume 200 ml) in doubling dilutions of test compounds and
plates were incubated under standard conditions for 48 h, after
which the blue, non-fluorescent indicator dye Alamar Blue
(resazurin sodium salt; Sigma) was added and the plates were
incubated for a further 24 h. Pentamidine was used as positive
control throughout, with drug-free incubations as negative control
(4 per plate). All drugs were doubly diluted over 23 wells with a
starting concentration of test compound of 5 mM for pyrimidines
and of 100 mM for pentamidine.
Flow cytometry
The DNA content of bloodstream trypanosomes was deter-
mined exactly as described [36]. Briefly, trypanosome samples
were fixed o/n in methanol:PBS (7:3, v/v), treated with RNase
and stained with propidium iodide (both Sigma) and analysed with
a FACSCalibur (Benton Dickinson) using the FL2-area detector.
Quantitative PCR of Uridine Phosphorylase
RNA isolated from WT s427 and PYR6-52/2 cells was
quantified using a Nanodrop (Thermo Scientific); 2 mg of RNA
was diluted in RNase-free water to a total volume of 25 ml.
Complementary DNA (cDNA) was produced using a Reverse-
Transcriptase (RT) kit (Primerdesign, UK). cDNA for each sample
was diluted 1:10 and then used for Real Time-PCR. Amplification
of cDNA was performed in a 7500 Real Time PCR System
(Applied Biosystems). The dissociation curve was used to ensure
the amplification of only one product; samples without RT or
cDNA were used as controls. The constitutively expressed gene
GPI8 [37] was used as endogenous control, with primer sequences
59- TCTGAACCCGCGCACTTC and 59-CCACTCACG-
GACTGCGTTT. For uridine phosphorylase (UP), the DDCT
method was used for relative quantification (RQ) using WT cells in
HMI-9 as a calibrator or internal control. Data was analyzed using
Applied Biosystems 7500 SDS Real-Time PCR systems software.
Primers used for the amplification of UP were 59-
TTTGACCCCTCCACCATGA and 59-GATTCAGCAGGT-
GAGCCACAA. The entire experiment was performed on three
independent occasions, starting from cell culture and RNA
isolation.
Infectivity in mice
Six-weeks-old female ICR (CD-1) Swiss outbred mice (Harlan)
were divided into 3 groups of six mice each. Mice were injected
intraperitoneally with 105 bloodstream forms of Trypanosoma brucei
brucei strains .427 WT, Pyr6-5+/2 and Pyr6-52/2 in 200 ml of
HMI-9 medium supplemented with 10% FBS. To quantify
parasitaemia, 1 ml of blood was daily harvested by tail venepunc-
ture of each infected mice and appropriately diluted in red blood
cell lysis buffer (Sigma). 10 ml of the diluted cells was examined
under a light microscope using a haemocytometer and parasitae-
mia was expressed as number of parasites per ml blood.
Results
Generation and confirmation of pyrimidine auxotrophic
T. brucei
A schematic representation of the generation of a PYR6-52/2
strain is shown in Figure 1A. Plasmids with the positive selection
marker hygromycin phosphotransferase (HYG) and the negative
selection marker Herpes simplex virus thymidine kinase (HSVTK)
(generous donation from George Cross, Rockefeller University,
New York) were used. Bloodstream form T. b. brucei s427 (16106
cells ml21) were transformed with the loxP-HYG-HSVTK-loxP
cassette using an Amaxa Nucleofector. The transformants were
grown in selective medium containing 4.5 mg ml21 hygromycin
(Sigma) and were cloned using limiting dilution, creating a
heterozygote PYR6-5+/2 strain. Viable clones with the desired
insert were subjected to increasing drug pressure with 5-
fluoroorotic acid (5-FOA) leading to loss of the second PYR6-5
gene (loss of heterozygosity) at 100 mM (Fig. 1B). Loss of
heterozygosity (LOH) and the generated homozygous PYR6-52/2
were further confirmed using Southern blot (Fig. 1C).
Growth of pyrimidine auxotrophs on different pyrimidine
sources
Under standard culture conditions there was no clear growth
phenotype associated with loss of the PYR6-5 locus, as growth of
the knockout cells in standard HMI-9 was similar to that of WT
s427 trypanosomes in HMI-9-tmd supplemented with 10% dialysed
FBS (Fig. S1). PYR6-52/2 cells were grown either in standard
HMI-9 or in HMI-9-tmd, which does not contain any pyrimidines
but does contain 1 mM hypoxanthine as a purine source (Table
S1) and is supplemented with FBS that was extensively dialysed to
remove small molecules such as nucleosides. As expected, PYR6-
52/2 cells were unable to grow in this semi-defined medium
without pyrimidines, and the trypanosome population rapidly
declined after 24 h (Fig. 2A,B). In contrast, a shift to purine-free
conditions only caused growth arrest after approximately 48 h
(Fig. 2B), consistent with previous observations in procyclic T.
brucei [38]. Evidently, any interruption in pyrimidine supply
rapidly makes trypanosomes non-viable and we investigated how
quickly the damage becomes irreversible (Fig. 2A), by adding back
Pyrimidine Auxotrophy in Trypanosoma brucei
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100 mM uracil at various times after passage of PYR6-52/2 to
HMI-9-tmd. Cells grew to the same density as in standard HMI-9
when uracil was added immediately after passage (0 h control) but
adding the uracil after as little as 12 h resulted in irreversible
growth arrest and the eventual death of the parasite population.
From 24 h, the addition of uracil was almost redundant, with the
cell population rapidly declining as in continuously pyrimidine-
free conditions (Fig. 2A).
We next tested the ability of these cells to grow on 100 mM or
1 mM (Fig. 3) of each natural pyrimidine nucleoside or
nucleobase. At the lower concentration, uracil supported near-
normal growth but at 1 mM appeared to have become somewhat
growth inhibitory and growth was less pronounced, possibly
Figure 1. Generation of Pyr6-5 Knockouts. (A) Schematic representation of the generation of Orotidine Monophosphate Decarboxylase
(OMPDCase) knockout. The first step is replacement of one PYR6-5 allele with a construct containing both positive selection marker hygromycin
phosphotransferase (HYG) and negative marker Herpes simplex virus thymidine kinase (HSVTK) between 34-bp loxP elements. The second step creates
the homozygous PYR6-52/2 through drug pressure with 5-fluoroorotic acid (5 FOA), causing loss of heterozygosity. (B) PCR analysis of the PYR6-5
gene, generating an 870 bp amplicon as described in the Materials and Methods section confirmed the absence of the gene in Pyr6-52/2 (lane 1) and
its continued presence in Pyr6-5+/2 (lane 2). Lane 3 is the control with WT s427 DNA. (C) Southern blot confirming knockout strategy, using probes for
the PYR6-5 locus and for the HYG-HSVTK cassette. Lane 1, Pyr6-52/2, lane 2, Pyr6-5+/2, Lane 3, WT s427. Band ‘a’ is PYR6-5, band ‘b’ is HYG-HSVTK.
doi:10.1371/journal.pone.0058034.g001
Figure 2. Growth of bloodstream form T. b. brucei in media with various purine and pyrimidine content. A. Pyr5-62/2 trypanosomes
were transferred from HMI-9 to HMI-9-tmd (pyrimidine-free,%) medium to which subsequently uracil was added to a final concentration of 100 mM at
the indicated time after seeding the culture. Samples were taken every 12 h and cell densities determined using a haemocytometer. In cultures with
conditions that allowed fast growth, the trypanosome population declined after 36–48 h due to overgrowth. Cell population in the ‘0 h’ group
declined after 60 h due to over-growth and exhaustion of the medium. B. Comparison of purine-free and pyrimidine conditions. WT s427 cells were
passaged from mid-log cultures (grown in standard HMI-9 into fresh cultures with the same medium (control,m) or the same medium without
hypoxanthine and supplemented with dialysed serum (purine free,N). Pyrimidine-auxotrophic T. b. brucei (PYR6-52/2) were transferred from standard
HMI-9 into HMI-9-tmd (pyrimidine-free, &) medium. Cell population in the ‘WT, HMI-9 control’ group declined sharply after 26–48 h due to over-
growth and exhaustion of the media.
doi:10.1371/journal.pone.0058034.g002
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because the resulting excessive uracil influx could cause an
imbalance between pyrimidine nucleotides and 29deoxyribonucle-
otides, or between purine and pyrimidine nucleotides. Uridine also
supported growth at 100 mM and even better at 1 mM, whereas
29-deoxyuridine barely had any effect at all at 100 mM. Of the
other pyrimidines, only cytidine had any effect on growth, and
only at 1 mM.
[3H]-Uracil uptake in pyrimidine auxotrophic
Trypanosoma brucei
We determined uracil uptake rates in Pyr6-52/2 and control
s427 WT cells to assess whether uracil uptake capacity in
bloodstream form T. b. brucei increased in the absence of
pyrimidine biosynthesis. WT and Pyr6-52/2 were grown in
standard HMI-9 and uptake of 0.15 mM [3H]-uracil was measured
in a timecourse over 120 s. The initial rate of uracil uptake was
consistently higher in the Pyr6-52/2 cells (Fig. 4A). The rates were
0.010960.0001 and 0.024160.0014 pmol(107 cells)21s21 for WT
and Pyr6-52/2 trypanosomes, respectively (n = 3; P,0.05, Stu-
dent’s T-test, unpaired). The increased uptake rate could not be
attributed to the expression of an additional uracil transporter in
the knockout strain not present in the WT cells, as Km values were
identical in both strains (0.3160.01 and 0.3460.03 mM, respec-
tively (n = 3)) and uracil transport was almost completely
insensitive to uridine in both strains (Ki values .3 mM, n = 3;
Fig. 4B). Indeed, uptake of 2.5 mM [3H]-uridine was almost
undetectable in both strains (data not shown). However, the Vmax
for uracil transport was significantly increased in Pyr6-52/2 cells
(0.1460.01 versus 0.08760.007 pmol(107 cells)21s21, respective-
ly; n = 3, P= 0.012) (Fig. 4C), consistent with the increased initial
rate seen in the time course, and probably reflecting a higher
number of the uracil transporter in the plasma membrane rather
than the expression of a different or additional transport protein.
Sensitivity of pyrimidine auxotrophic of trypanosomes to
pyrimidine analogues
We tested whether pyrimidine auxotrophs were more sensitive
to cytotoxic pyrimidine analogues and found that Pyr6-52/2 cells
are approximately one order of magnitude more sensitive to most
analogues, including 5-fluorouracil and 5-fluoro-29deoxyuridine
(Table 1). The only exception was 5-fluoroorotic acid, whose
action is dependent on OPRT and OMPDCase, and to which the
Pyr6-52/2 cells were completely impervious up to 5 mM although
WT trypanosomes were sensitive to this compound with an EC50
of 13.261.2 mM. Interestingly, the Pyr6-52/2 strain was also
sensitized to 5-fluorouridine whereas the WT cells were not
sensitive to this compound up to the limit tested (5 mM).
Expression of Uridine Phosphorylase in pyrimidine
auxotrophs
We observed that cultures of Pyr6-52/2 cells appeared to be
able to adapt to uridine as a sole pyrimidine source (data not
shown). In order to utilize uridine for the synthesis of pyrimidine
nucleotides they need to generate uracil from it, using uridine
phosphorylase (UP) [39]. We thus inferred that upregulation of UP
could be a possible adaptation to pyrimidine starvation and
performed quantitative PCR to assess relative UP mRNA levels in
WT and Pyr6-52/2 cells grown in different media. As shown in
Figure 5, UP expression was identical in WT cells grown in
standard HMI-9 or in HMI-9-tmd supplemented with 100 mM
uracil, but was significantly increased after 48 h growth on HMI-9-
tmd supplemented with 1 mM uridine (P,0.001). In Pyr6-52/2
cells cultured long-term in standard HMI-9 but transferred to
HMI-9-tmd/uracil for 48 h UP expression levels were higher than
for s427-WT under the same conditions (P,0.001) and the level
was further increased for Pyr6-52/2 cells grown 48 h in HMI-9-
tmd/uridine (P,0.001). These data appear to indicate that T. b.
brucei can adjust its UP expression levels to accommodate growth
on uridine as its sole pyrimidine source, whether these cells are
pyrimidine auxotrophs or prototrophs. We next investigated
whether Pyr6-52/2 strains can adapt when long-term cultured
on uridine as sole pyrimidine source. We found that these cells do
express significantly higher UP levels than s427-WT control cells
grown in standard HMI-9 or on HMI-9-tmd/uracil (P,0.01), but
revert quickly to control levels of expression when shifted to HMI-
9-tmd/uracil (Fig. 5).
The effect of pyrimidine starvation on DNA content and
integrity of pyrimidine auxotrophic T. b. brucei
Pyrimidine auxotrophs die relatively rapidly in the absence of a
salvageable pyrimidine source (uracil.uridine.29deoxyuridi-
ne.cytidine; see figure 3), with death of the population
progressing soon after 24 hours. To investigate the cause of the
rapid cell death we examined DNA content of the Pyr6-52/2 cells
grown in HMI-9-tmd supplemented with 100 mM of various
pyrimidines, using flow cytometry with the DNA-binding fluor-
Figure 3. Growth of pyrimidine auxotrophic T. b. brucei bloodstream forms on various pyrimidine sources. PYR6-52/2 cell cultures were
seeded at a density of 16105 cells ml21 and cultured at 37uC/5% CO2, either in normal HMI-9 or in a simplified pyrimidine version supplemented with
dialysed FBS and the indicated pyrimidine source at (A) 100 mM or (B) 1 mM. Samples were taken every 24 h and cell densities determined using a
haemocytometer, in duplicate. The experiment shown is representative of several similar experiments with essentially identical results. In cultures
with conditions that allowed fast growth, the trypanosome population declined after 36–48 h due to overgrowth.
doi:10.1371/journal.pone.0058034.g003
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ophore propidium iodide; Pyr6-52/2 cells grown in normal HMI-
9 served as control. We found that DNA content in control cells
presented a classical distribution of most cells in G1 phase
(diploid), a small proportion in S-phase undergoing DNA synthesis
and finally a percentage of the population in G2 phase (double set
of chromosomes) (Fig. 6). This profile was stable over the 48 hours
of the experiment, although the proportion in G2 phase increased
somewhat over this period, probably reflecting the mid-log phase
of growth of the population at the end of the experiment,
compared to early log phase at the start (% in G2 was 4.962.8%,
11.663.1% and 13.961.9% at 24 h, 36 and 48 h, respectively;
quantified using the ModFit software package). In sharp contrast,
there was a rapid increase in cells displaying an incomplete
complement of chromosomes in Pyr6-52/2 cells grown in HMI-9-
tmd, resulting both in cells with less fluorescence (i.e. less DNA) than
should be associated with normal G1 phase cells, or cells with a
DNA content between G1 and G2 phase (Fig. 6). This clearly
indicates that the cells are attempting cell division ‘as normal’ but
are unable to complete chromosome synthesis due to lack of
pyrimidine nucleotides, leading to aberrant cells with incomplete
and fragmented chromosomes that are ultimately non-viable. This
phenomenon progressed rapidly and at 48 h few live cells could be
detected. The cells that could be counted by the flow cytometer
almost all contained incomplete and presumably fragmented
DNA. Highly similar flow cytometry results were obtained when
supplementing HMI-9-tmd with cytosine, thymine or thymidine,
whereas supplementation with uracil or uridine produced profiles
highly similar to the control (growth in standard HMI-9); addition
of 29deoxyuridine, cytidine or 29deoxycytidine resulted in inter-
mediate levels of DNA damage over 48 h (results not shown). In
an effort to quantify the emergence of aberrant cells the flow
Figure 4. Uracil transport by T. b. brucei bloodstream forms. (A) Timecourse of 0.15 mM [3H]-uracil uptake by WT s427 and by PYR6-52/2 cells,
in the presence or absence of 1 mM unlabelled uracil, as indicated. Dashed lines represent linear regression over the first 50 s, yielding correlation
coefficients of 0.97 and 0.92 for the knockout and WT strains, respectively. In the presence of excess unlabelled uracil uptake was not significantly
different from zero (F-test) for both strains. The experiment shown is representative of three identical experiments with highly similar outcomes and
shows average and SE of triplicate determinations. In the presence of 1 mM uridine, the lines for WT and PYR6-52/2 were superimposed. (B) Uptake of
[3H]-uracil by PYR6-52/2 trypanosomes was measured over 30 s in the presence or absence of unlabelled uracil (#) or uridine (&) at the indicated
concentrations. The data was plotted to a sigmoid curve with variable slope which in the case of uridine inhibition was set at zero for its minimum.
The data are the average and SE of triplicate determinations and the experiment shown is representative of several independent experiments with
essentially identical outcomes. (C) Michaelis-Menten saturation plots for uracil uptake of [3H]-uracil by WT (#) or PYR6-52/2 (&) T. b. brucei
bloodstream forms. The data represents the average and SE of three identical experiments, each performed in triplicate.
doi:10.1371/journal.pone.0058034.g004
Table 1. EC50 values for some pyrimidine analogues tested
on WT s427 and PYR6-52/2 bloodstream forms grown in
standard HMI-9, using a standard protocol based on the
fluorescent indicator dye Alamar Blue.
WTs427 PYR6-52/2 RF P value
AVG ± SE
(mM) n
AVG ± SE
(mM) n
5-Fluorouracil 35.961.5 4 2.360.07 4 0.06 ,0.001
5-Fluoro-29deoxyuridine 4.660.5 3 0.7760.10 3 0.16 0.002
5-Fluoro-29deoxycytidine 43.764.4 3 4.660.9 3 0.105 ,0.001
5-Fluorouridine .5000 5 47263 3 ,0.09 ,0.001
5-Fluoroorotic acid 13.261.2 3 .5000 4 .380 ,0.001
RF, resistance factor, being the ratio of the EC50 values (mM) for knockout over
WT strains. P value is based on an unpaired Students t-test.
doi:10.1371/journal.pone.0058034.t001
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cytometry profiles were analyzed with the ModFit software
package which models the peak area. This was not successful for
the 48-h time points because of the lack of viable cells and too
extensive DNA damage, which did not allow reliable estimates of
relevant peaks. However, some results for the 24-h and 36-h time
points are shown in figure 7. The use of thymidine as sole
pyrimidine source caused a highly significant increase in cells in
G2 phase, possibly because of the anticipated imbalance between
thymidine nucleotides and deoxycytidine nucleosides, which the
cell cannot generate from thymidine. The peak classified as ‘DNA
debris’ increased within 24 h of pyrimidine-free conditions and
this was highly significant (P,0.01) after 36 h; the debris amount
was also significantly increased by culturing on thymidine (Fig. 7).
We conclude that any significant interruption of pyrimidine
nucleotide availability leads to major defects in DNA synthesis.
Infectivity of pyrimidine auxotrophic of T. b. brucei in
mice
The observation (Fig. 3) that pyrimidine auxotrophic Pyr6-52/2
cells grow in standard HMI-9, which contains only thymidine as a
pyrimidine source, but cannot grow in thymidine-supplemented
medium with dialyzed FBS strongly suggest that (1) T. b. brucei
cannot use thymidine as its sole pyrimidine source and (2) it is able
to salvage sufficient amounts of other pyrimidines from the non-
dialyzed serum. It could thus be speculated that pyrimidine
auxotrophic trypanosomes should be able to survive in vivo. To test
this, we infected groups of 6 mice with a high inoculum of 105
trypanosomes of s427-WT, Pyr6-5+/2 or Pyr6-52/2 strains and
followed survival and parasitaemia for 15 days. Figure 8A shows
that WT trypanosomes were the most virulent and killed all mice
between 4 and 8 days. The single allele knockout strain Pyr6-5+/2
caused the death of four mice by day 5 but two of the animals
survived until day 12. In contrast, all the animals inoculated with
Pyr6-52/2 survived until day 15, when the experiment was
terminated. However, the auxotrophs were able to survive and to
multiply in the host, as evidenced by the average parasitaemia,
which reached similar levels as for the other strains albeit much
more slowly (Fig. 8B). We conclude that T. brucei can salvage just
enough uracil and/or uridine in vitro to maintain an infection.
Discussion
Kinetoplastid parasites are able to salvage preformed pyrimi-
dine nucleobases and/or nucleosides [6,7,15,40,41] as well as
synthesise them de novo from glutamine and aspartate [42]. The
two pathways converge at UMP, the end-product of the 6-step
biosynthesis pathway as well as the nexus for salvaged cytidine,
uridine, 29dUrd, 29dCtd and uracil, through the actions of cytidine
deaminase, uridine phosphorylase and uracil phosphoribosyltrans-
ferase (UPRT). From UMP the cell can then make all pyrimidine
ribonucleotides and 29deoxyribonucleotides that it needs, through
non-redundant pathways. Salvaged thymidine can be utilised as
thymidine nucleotides but not to produce any other pyrimidine
nucleotides ([24]; reviewed in 10 and 19) and both procyclic and
bloodstream form trypanosomes take up thymidine very poorly
[16,24]. Therefore it is clear that pyrimidine metabolism in
protozoa must be replete with good drug targets. Indeed, T. b.
brucei DHFR-TS, CTP synthetase and dUTPase have all been
shown already to be essential enzymes [20,21,22]. These enzymes
are all in the pathways downstream from UMP and thus shared by
the salvage route and the biosynthesis route.
What is less clear is whether either of the two biochemical
pathways to obtain UMP in the first place might be essential and
thus a potential drug target. In order to therapeutically target the
salvage pathway to UMP it would be necessary to inhibit either the
uptake of uracil, uridine, 29deoxyuridine, cytidine and 29deoxy-
cytidine, or to inhibit UPRT. With regards to the former option it
should be noted that cytidine and 29deoxycytidine are incorpo-
rated very poorly into the T. b. brucei nucleotide pool [21,24] and it
would thus only be necessary to inhibit the carriers for uracil,
29deoxyuridine and uridine, and we recently reported that all
three are mediated by the same transporter, TbU3, in bloodstream
forms [24]. However, we report here that WT trypanosomes (i.e.
pyrimidine prototrophs) grow almost unimpeded in the absence of
any pyrimidine source and must conclude that neither pyrimidine
transporters nor UPRT are essential functions in bloodstream
form T. b. brucei - consistent with a recent report that deletion of
UPRT in L. donovani promastigotes created a pyrimidine proto-
trophic parasite with normal in vitro growth [43]. It can thus be
concluded that pyrimidine salvage is not an essential function for
trypanosomes.
Arakaki et al [25] previously investigated whether the de novo
biosynthesis route to UMP was essential to T. b. brucei in vitro; they
employed RNA-interference (RNAi) to reduce expression of T.
brucei dihydroorotate dehydrogenase (DHODH). These authors
reported that knockdown of this enzyme did not affect growth in
standard HMI-9 but greatly reduced growth in pyrimidine-
depleted medium using a commercial dialysed serum. Our own
observations with a PYR6-52/2 strain are entirely consistent with
Arakaki’s report: the growth rate of pyrimidine auxotrophs is at
most slightly affected in normal medium with non-dialysed serum.
As shown in the Supplementary data, thymidine (,83 mM) is the
Figure 5. Comparative expression of uridine phosphorylase in
wild-type and pyrimidine auxotrophic trypanosomes. Expres-
sion of uridine phosphorylase (UP) was assessed by Real Time PCR in
WT and PYR6-52/2 strains grown under various conditions. The results
are presented normalized to the control (group1) and are the average
and SE of 8 replicates. 1. Control: WT grown in HMI-9; 2. WT grown 48 h
in HMI-9-tmd+100 mM uracil; 3. WT grown 48 h in HMI-9-tmd+1 mM
uridine; 4. PYR6-52/2 grown 48 h in HMI-9-tmd+100 mM uracil; 5. PYR6-
52/2 grown 48 h in HMI-9-tmd+1 mM uridine; 6. PYR6-52/2long-term
adapted to growth on uridine, grown 48 h in HMI-9-tmd+100 mM uracil;
7. PYR6-52/2long-term adapted to growth on uridine, grown 48 h in
HMI-9-tmd+1 mM uridine. Data were analysed with a one-way ANOVA
with Tukey’s correction. Horizontal asterisks indicate significant
differences from control; vertical asterisks indicate significant differenc-
es between individual bars as indicated.
doi:10.1371/journal.pone.0058034.g005
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only pyrimidine added to that medium but since this nucleoside
cannot be converted to uridine and cytidine nucleotides by T. b.
brucei, it is redundant [24,25] and clearly the serum provides
sufficient pyrimidines for growth, consistent with the average
uracil concentration of 0.1760.05 mM in human plasma [44] and
high affinity uptake of pyrimidines, particularly uracil, by T. brucei
[23,24]. We thus conclude that pyrimidine biosynthesis is not
essential for in vitro growth, and the fact that even 10% FBS
supplies sufficient pyrimidines, seems to indicate that it may not be
essential for in vivo growth either.
This was tested by infecting mice with s427-WT, PYR6-5+/2
and PYR6-52/2 trypanosomes. All three strains were able to
maintain an infection and although the homozygous knockout
strain was clearly less virulent, it unambiguously establishes that
inhibition of the de novo pyrimidine biosynthesis is not a viable
therapeutic strategy against African trypanosomes. These findings
are very similar to those reported for promastigote L. donovani [28]
but, in contrast to the authors of that report, we contend that the
fact that disruption of pyrimidine biosynthesis can be compensated
for by physiological levels of pyrimidines demonstrates that this
pathway is not essential in kinetoplastids, and not a viable drug
target. Indeed, the same authors very recently demonstrated that
L. donovani that lack carbamoyl phosphate synthetase, and are thus
pyrimidine auxotrophic, were able to establish a ‘robust’ infection
in mice [43]. It is noteworthy, however, that Leishmania species are
obligated intracellular parasites and that this manuscript is the first
assessment of in vivo growth of an extracellular pyrimidine-
auxotrophic protozoan. This is relevant as the intracellular and
extracellular nucleoside and nucleobase levels are potentially very
different, with the intracellular purines and pyrimidines over-
whelmingly existing as nucleotides, which cannot be taken up
directly by protozoan transporters [6]. In addition, a previous
report on pyrimidine-auxotrophic Toxoplasma gondii, another
obligate intracellular protozoan, showed that these parasites were
completely avirulent even in immunocompromised mice [45] - a
phenotype attributed to the lack of free pyrimidines within animal
cells which also prevents growth of pyrimidine auxotrophic
bacteria [46].
Inhibition of the pyrimidine biosynthesis pathway in T. b. brucei
greatly sensitises the trypanosomes to cytotoxic pyrimidine
analogues such as 5-fluorouracil, 5-fluoro-29deoxyuridine, 5-
fluorodeoxycytidine and 5-fluorouridine (Table 1). The enhanced
effect of 5-fluorouracil was also noted by Arakaki et al [25], who
attributed it to inhibition of uracil uptake. Whilst this analogue is
indeed a competitive inhibitor of uracil transport in T. brucei, none
of these fluorinated pyrimidines would sufficiently inhibit uracil
uptake in bloodstream forms at the EC50 values given in Table 1,
especially not 5F-29deoxyuridine or 5F-29deoxycytidine [24]. As
an alternative explanation, we propose that these fluorinated
pyrimidines enter the trypanosomes as prodrugs and subversive
substrates for the pyrimidine salvage enzymes, are converted to
nucleotides and incorporated into nucleic acids, as indeed is the
case in mammalian cells [47] and as we have recently shown for 5-
fluorouracil in T. b. brucei [24]. This incorporation is more efficient
in the absence of a newly synthesised pool of pyrimidine
metabolites that would compete with the halogenated analogues
at the level of each enzyme as well as for RNA and/or DNA
polymerases.
We thus conclude that an inhibitor of any one of the enzymes of
the de novo pathway together with either an inhibitor of uracil/
uridine uptake, or with a cytotoxic nucleoside analogue, would be
a powerful and synergistic combination that would act on
trypanosomes through both misincorporation of false nucleotides,
and by causing pyrimidine starvation through inhibition of
pyrimidine carriers, and we found that trypanosome populations
die much more quickly from a lack of pyrimidines than from a lack
Figure 6. Flow cytometry for DNA content in bloodstream form PYR6-52/2 cells. Pyrimidine auxotrophic trypanosomes were either
incubated in standard HMI-9 or, in parallel, in pyrimidine-free HMI-9-tmd for up to 48 h, stained with propidium iodide and prepared for flow
cytometric analysis. Whereas control cultures show a classical distribution of cells in G1, S and G2 phase, as well as a small percentage of cells with
less than the normal diploid DNA content (debris, d), cells grown in pyrimidine-free medium showed a much higher percentage of cells with partial
DNA content, and this increased dramatically between 24 and 48 h.
doi:10.1371/journal.pone.0058034.g006
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Figure 7. Quantitative analysis of DNA content in pyrimidine-starved trypanosomes. The peak area of G1, G2 and debris of flow
cytometric analysis of DNA content (Fig. 6) was determined using the ModFit software package after 24 or 36 of growth under various culturing
conditions. Growth was in HMI-9 (control) or in HMI-9-tmd with or without the addition of 100 mM of one pyrimidine as indicated. The data are the
average of 3–6 independent determinations and statistical analysis was performed using one-way ANOVA with Tukey’s correction (Prism 5,
GraphPad). *, P,0.05; **, P,0.01.
doi:10.1371/journal.pone.0058034.g007
Figure 8. Infectivity of pyrimidine auxotrophic T. b. brucei. (A) Survival of mice in groups of 6, each inoculated with 105 bloodstream form
trypanosomes of various clonal lines. (B) Parasitaemia of the same mice as depicted for survival in panel A. The average parasitaemia of the surviving
mice is shown. Detection was by phase-contrast microscopy and detection limit was 16104; where the infected was sub-patent, a value of 5000 cells
ml21 was inserted in order to arrive at a reasonable average. Both panels: #, WT s427; &, PYR6-5+/2; m, PYR6-52/2.
doi:10.1371/journal.pone.0058034.g008
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of purines [38]. It can easily be speculated that kinetoplastid
parasites, having evolved without the capacity to synthesise their
own purines, must be relatively well-adapted to periods with
relatively low purine availability, as demonstrated by the
reversibility of purine starvation-induced growth arrest [38]. In
contrast, they have not needed to develop a mechanism to cope
with a prolonged dearth of pyrimidines, being able to make
sufficient amounts themselves, and trypanosomes are therefore
unable to recover from even short periods of pyrimidine
starvation. We did observe, consistently, increased expression of
uridine phosphorylase, and an increase in uracil uptake capacity
(both about two-fold), in pyrimidine-starved trypanosomes but this
hardly constitutes a major upregulation of the pyrimidine salvage
pathway and it is at best uncertain whether this is a regulated,
physiological response to low pyrimidine levels. Indeed, the lack of
a regulated response to the insufficient level of pyrimidine
nucleotides was manifest in the major defects in DNA synthesis
after only 24 h, leading to fragmented and incomplete chromo-
somes.
In summary, we have shown that neither pyrimidine uptake or
de novo biosynthesis is essential in African trypanosomes but that a
drug combination targeting both systems would be a very powerful
approach to novel therapeutic approaches against kinetoplastid
parasites.
Supporting Information
Figure S1 Growth of PYR6-52/2 T. b. brucei blood-
stream forms in standard HMI-9 and s427-WT in HMI-
9-tmd supplemented with 10% dialysed FBS. Seeding
density was 16105 cells ml21 and cells were manually counted
every 24 h. On day 3 cells were passaged to relevant fresh
medium, again at 16105 cells ml21.
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